S&P 500 rides Apple-led tech rally higher
Investing.com - TG Therapeutics (NASDAQ:TGTX) shares dropped 14% after the company reported second-quarter Briumvi sales that met analyst expectations but failed to impress investors. According to InvestingPro data, the stock remains undervalued despite delivering an impressive 89.3% return over the past year. The company maintains strong fundamentals with an exceptional gross profit margin of 87.4%.
The biotech firm posted Briumvi revenue of $138.8 million, exceeding company guidance of $135 million but aligning with consensus estimates of $138 million, according to BofA Securities. InvestingPro analysis reveals multiple positive indicators for the company, including expected net income growth and strong liquidity position. Subscribers can access 10+ additional ProTips and comprehensive valuation metrics in the Pro Research Report.
TG Therapeutics raised its 2025 Briumvi revenue guidance to $570-575 million, slightly below the consensus expectation of $578 million that analysts had projected before the earnings announcement.
The company indicated that growth would be stronger in the fourth quarter compared to the third quarter due to seasonality impacts, a pattern consistent with previous years’ performance.
BofA Securities maintained its Underperform rating and $11 price target on TG Therapeutics, noting that the uptake of subcutaneous options would be a key factor to monitor for the remainder of 2025 and into 2026.
In other recent news, TG Therapeutics Inc . reported its financial results for the second quarter of 2025, showing a mixed performance. The company announced earnings per share (EPS) of $0.17, which fell short of the forecasted $0.19, marking a 10.53% negative surprise. Despite this, TG Therapeutics exceeded revenue expectations by reporting $141.1 million, surpassing the anticipated $137.4 million, resulting in a 2.69% positive surprise. These recent developments reflect the company’s ongoing financial activities and investor reactions. The company’s performance in terms of revenue was a highlight, even as the EPS miss drew some concern. This financial report provides investors with insights into the company’s current standing and market position. The focus remains on how TG Therapeutics will navigate these mixed results moving forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.